30 Oct 2025 | 3 Mins Read
Cipla's US sales may be impacted by Revlimid competition
Flipitmoney
Cipla's US sales are expected to drop 12% to $220 million due to higher competition for Revlimid Generic. The quarterly revenue is predicted to grow 5% to ₹7,370 crore, with EBITDA flat. Domestic formulations business is expected to grow in high-single digits, while the European Union and Rest of World markets may see growth of 8-10%.